Scientists test 'Off-the-Shelf' cell therapy for tough leukemias

NCT ID NCT07109518

Summary

This early-stage study is testing the safety and finding the right dose of a new type of CAR-T cell therapy for adults with CD7-positive blood cancers that have come back or not responded to other treatments. The therapy uses 'universal' donor cells, which are not taken from the patient, and is being given to small groups of people with acute myeloid leukemia or T-cell leukemia/lymphoma. The main goal is to see if the treatment is safe and to learn how well it might work against these aggressive cancers.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Institute of Hematology & Blood Diseases Hospital

    RECRUITING

    Tianjin, Tianjin Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.